TWELVE-MONTH FOLLOW-UP OF DEXAMETHASONE IMPLANTS FOR MACULAR EDEMA FROM VARIOUS DISEASES IN VITRECTOMIZED AND NON-VITRECTOMIZED EYES: RESULTS FROM THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP

Abstract

Purpose : To evaluate the best corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes.

Methods : This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7-mg intravitreal dexamethasone implant for 12 months. The best-corrected VA (BCVA), CRT, intraocular pressure (IOP), need for cataract surgery, safety data, and number of implants were recorded.

Results : Vitrectomized and nonvitrectomized eyes received means of three and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%).

Conclusions : The dexamethasone implant administered PRN improved VA and decreased CRT in ME, with possible long-term clinically relevant benefits for treating ME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.